Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Duality Biotherapeutics, Inc. ( (HK:9606) ) has shared an announcement.
Duality Biotherapeutics, Inc. has addressed recent fluctuations in its stock trading price and volume, which coincided with the release of preliminary data on its ADC candidates at the 2025 American Society of Clinical Oncology Annual Meeting. The company clarified that the information released does not constitute inside information and there is no known reason for the stock fluctuations, assuring stakeholders that operations remain normal.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$270.34 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of Antibody-Drug Conjugates (ADCs). The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 806,729
Find detailed analytics on 9606 stock on TipRanks’ Stock Analysis page.